Apolipoprotein J and Alzheimer's amyloid beta solubility. - Wikidata - wikimedia - TriplyDB

Apolipoprotein J and Alzheimer's amyloid beta solubility.

Apolipoprotein J and Alzheimer's amyloid beta solubility.

http://www.wikidata.org/entity/Q42160133

about

beta -Amyloid peptide-induced apoptosis regulated by a novel protein containing a g protein activation module Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Disorder-to-order conformational transitions in protein structure and its relationship to disease.Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein.Replication of CLU, CR1, and PICALM associations with alzheimer disease.Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease.The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE.Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice Alzheimer's disease risk genes and mechanisms of disease pathogenesis Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease.Immunization treatment approaches in Alzheimer's and prion diseases.A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.Apolipoprotein Abeta: black sheep in a good family.TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ.Clusterin associates with altered elastic fibers in human photoaged skin and prevents elastin from ultraviolet-induced aggregation in vitro Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease.Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases.Clusterin Binds to Aβ1-42 Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation.Alzheimer's soluble amyloid beta is a normal component of human urine.Search for amyloid-binding proteins by affinity chromatography.Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity.Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke.Brain site-specific proteome changes in aging-related dementia.Increased clusterin expression in Fuchs' endothelial dystrophy.Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration.The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.Therapeutic strategies against protein misfolding in neurodegenerative diseases.Apolipoprotein E receptor pathways in Alzheimer disease.Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy.Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.Genetic association between clusterin polymorphisms and Alzheimer's disease in a Japanese population.Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells.Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways.

P2860

Q24291033-654B62DC-7F22-4BA4-86A3-FC859084D3E5 Q24298795-89F7007A-A6D2-4FF8-B420-FAB4F81B8426 Q24302165-D52A8AA3-71D5-40E9-971F-8E208A91992F Q24612662-8622F886-2CAD-48CE-B833-E6336C2F8AC0 Q28504767-07B1F957-474C-417E-932E-09DEC250C34A Q29547593-32B4EBFC-A1BF-46C6-9320-DB6765F9E727 Q30376073-8A365706-E5C4-46F6-BDDB-3C44298125B2 Q33998693-979D04F4-EC6D-4774-A644-A194D2199EEA Q34058002-32BF2D45-5D51-4EFA-9C27-64E46725F7E0 Q34089188-C7865E17-5F7D-455E-92F6-7F28FD22EF58 Q34123651-DF30B9DB-7F06-4057-AEF7-63111CA20A52 Q34299304-DBD26FE0-E7CA-4733-9184-782C28B39DA9 Q34425904-A5757246-82D4-44A7-88B9-D370DD1E4AFF Q34721350-B9B6781D-0A4F-4B13-83C7-C4ABB51F226E Q34778095-5B0691BF-08A7-4856-9613-1D8385AE78D6 Q35103136-2143B8E8-C58D-47A6-B5C4-B602C9186103 Q35115904-E0BAF34B-FD25-407D-BF2C-262A28D85D2D Q35745403-CE335AA0-80E8-44A1-A6B6-9954659E2D83 Q35987625-B8FBC035-E599-4630-B015-C6E5F0048153 Q36071985-B18FD6F6-7F7D-4A2C-9B0D-5E6AD000E5EB Q36095591-0DD9B4D8-3047-47D8-AF41-97D796E28B1C Q36600561-2C7A8C7F-30FC-4F99-B1E5-372BEAACAE3D Q36647438-3E96D6CE-F0AE-47B2-B69C-CCDD7B274032 Q36727420-1CF1959D-34D8-47DA-9BB6-021E95684ECC Q36865008-E034B78D-2F32-4708-8AB7-0D53A7A1BEAD Q36880203-11AB4F45-B9BB-4D40-AEFA-079E216FBBAF Q37030603-EFA69756-3AEB-4C5A-9B12-B1EF1E89AA2D Q37105427-B1586F2C-AB1D-450A-BF4D-B106F2C59F6E Q37212178-1A32B510-FB37-46DC-A17B-502ED75F8533 Q37462121-F4316E26-D581-4C6A-ADA1-20B385F47552 Q37583628-9FD2C6A2-8844-491F-BBBE-85512CE649B0 Q37978548-0044A4AC-6FBA-4358-9336-8044B0E18402 Q38088318-8909CC15-2176-4197-B061-D1FFB3756595 Q38194104-C2DDDDB8-5ED6-4019-A490-69A393268030 Q39135845-EA306105-5765-44BD-8F1F-EA9CDD112448 Q39443274-07C963BF-A2D5-4119-8AC1-495B92899AD8 Q39559518-A33E1603-CFCE-4279-89EA-3D885C23BC03 Q39766608-BCE2441E-1520-499C-8E19-E47D81A3D19D Q40237512-181FE7DA-0F3A-43B2-A27F-CD0C1247C73C Q41476892-7554C68C-7674-4684-9CA0-EAADAF141504

P2860

Apolipoprotein J and Alzheimer's amyloid beta solubility.

http://www.wikidata.org/entity/Q42160133

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Apolipoprotein J and Alzheimer's amyloid beta solubility.

@en

Apolipoprotein J and Alzheimer's amyloid beta solubility.

@nl

type

label

Apolipoprotein J and Alzheimer's amyloid beta solubility.

@en

Apolipoprotein J and Alzheimer's amyloid beta solubility.

@nl

prefLabel

Apolipoprotein J and Alzheimer's amyloid beta solubility.

@en

Apolipoprotein J and Alzheimer's amyloid beta solubility.

@nl

P1433

Q42160133-85D80D8D-7D37-40CF-8841-92D1A0BA57DD

P1476

Q42160133-D4ACBA69-F871-41EB-A0EC-03DCEFFFF7F1

P2093

Q42160133-098CDF94-536F-4E41-9576-C7C34CB27754

Q42160133-12ACC325-C45D-41CB-841B-858F8E82A5D3

Q42160133-1566DBF0-C637-4A5E-B95F-20F271FF2442

Q42160133-2C325696-10CC-4A73-8369-3930354DE83C

Q42160133-D5BE67AF-7D4F-461B-A377-CD4D6E5DD200

P2860

Q42160133-06AA1392-5FA6-4021-9CC8-E81206266B5A

Q42160133-0E53346B-C7BD-44F3-9FB9-F0677516AFCA

Q42160133-1A7DF72A-2AAB-4F87-9CC6-016D704C60CF

Q42160133-1F4173B3-4B4D-465E-8323-CD2B2D86A280

Q42160133-26844FB7-5AA1-4003-9A55-9C4B56DD2F6E

Q42160133-2E4972D0-99FB-446A-B322-589AAB7C32E5

Q42160133-33AD7825-DF42-4032-9160-0BD737455D45

Q42160133-34B19B9B-2440-44D2-942D-6C9E7D2E106E

Q42160133-364EF0C7-304C-49B4-994D-543035A423F6

Q42160133-381AF718-0090-45AA-8330-A3EB59867A28

P304

Q42160133-5B07FC0F-E8AA-482B-9C98-D5D1A0B54542

P31

Q42160133-7A991183-16BF-4A76-B051-86E43CACE910

P356

Q42160133-FF334D03-DA46-491B-8C19-85E42A62870B

P407

Q42160133-F5D1D099-65BF-4806-8579-33A747E397D9

P478

Q42160133-2BC6B062-A936-4751-B9B3-60B2D804CCD6

P577

Q42160133-2B9A9B57-BBD4-440A-8C1F-77B2E71FC025

P5875

Q42160133-D2A3ADB7-7BF3-458A-9563-EE06AF89321C

P698

Q42160133-4C68EF8C-FDE3-4506-A01E-646158D317FE

P921

Q42160133-82EF2933-A7FE-483C-8745-332CD3410C4F

P932

Q42160133-EBC530EF-E0AC-473D-8E94-6433DC302C16

P356

P1433

Biochemical Journal

P1476

Apolipoprotein J and Alzheimer's amyloid beta solubility.

@en

P2093

B Frangione

http://www.w3.org/2001/XMLSchema#string

C Soto

http://www.w3.org/2001/XMLSchema#string

E Matsubara

http://www.w3.org/2001/XMLSchema#string

J Ghiso

http://www.w3.org/2001/XMLSchema#string

S Governale

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin

Amyloid plaque core protein in Alzheimer disease and Down syndrome

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths.

Differences between vascular and plaque core amyloid in Alzheimer's disease.

Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family.

P304

671-679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/BJ3160671

http://www.w3.org/2001/XMLSchema#string

P407

P478

316 ( Pt 2)

http://www.w3.org/2001/XMLSchema#string

P577

1996-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14515179

http://www.w3.org/2001/XMLSchema#string

P698

8687416

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

1217400

http://www.w3.org/2001/XMLSchema#string